Vivos Therapeutics (NASDAQ:VVOS) and EOM Pharmaceutical (OTCMKTS:IMUC) Head to Head Analysis

EOM Pharmaceutical (OTCMKTS:IMUC) and Vivos Therapeutics (NASDAQ:VVOS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Profitability

This table compares EOM Pharmaceutical and Vivos Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
EOM Pharmaceutical	N/A	N/A	N/A
Vivos Therapeutics	-127.70%	-2,325.64%	-98.12%

Valuation and Earnings

This table compares EOM Pharmaceutical and Vivos Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
EOM Pharmaceutical	N/A	N/A	-$1.92 million	N/A	N/A
Vivos Therapeutics	$19.57 million	0.43	-$21.17 million	($2.14)	-0.29

EOM Pharmaceutical has higher earnings, but lower revenue than Vivos Therapeutics.

Insider & Institutional Ownership

26.4% of Vivos Therapeutics shares are held by institutional investors. 3.3% of EOM Pharmaceutical shares are held by company insiders. Comparatively, 2.1% of Vivos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Risk & Volatility

EOM Pharmaceutical has a beta of -0.18, indicating that its share price is 118% less volatile than the S&P 500. Comparatively, Vivos Therapeutics has a beta of 6.25, indicating that its share price is 525% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for EOM Pharmaceutical and Vivos Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
EOM Pharmaceutical	0	0	0	0	0.00
Vivos Therapeutics	1	1	2	0	2.25

Vivos Therapeutics has a consensus price target of $2.75, suggesting a potential upside of 350.82%. Given Vivos Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Vivos Therapeutics is more favorable than EOM Pharmaceutical.

Summary

Vivos Therapeutics beats EOM Pharmaceutical on 6 of the 11 factors compared between the two stocks.

About EOM Pharmaceutical

Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey.

About Vivos Therapeutics

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.